

#51703

Date: December 30, 2022

Subject: Catalyst Biosciences, Inc. - Cash Distribution and Exercise

Consideration

Option Symbol: CBIO Date: 01/13/2023

Catalyst Biosciences, Inc. (CBIO) has announced a Special Cash Dividend of \$0.24 per CBIO Common Share. The record date is January 5, 2023; the payable date is January 12, 2023. The ex-distribution date for this distribution will be January 13, 2023.

NOTE: CBIO will also grant one non-transferrable CVR per CBIO share to shareholders as of the January 5, 2023 record date. The CVR represents a non-transferable contractual right to receive additional payments, as described in the 8-K dated December 22, 2022. CBIO options will not be adjusted to call for the delivery of the CVRs.

<u>Exercise Consideration</u> - CBIO options will <u>not</u> be adjusted to include the non-transferable CVRs. Call holders who wish to ensure entitlement to the Contingent Value Rights must exercise their options in sufficient time to become a holder of record to receive the non-transferable CVRs. In all cases, it is the sole responsibility of persons holding call options seeking entitlement to the non-transferable CVRs to determine when to exercise their options.

Contract Adjustment

Effective Date: January 13, 2023

New Multiplier: 100 (e.g., for premium extensions a premium of 1.50 equals \$150.00;

a strike of 1.07 yields \$107.00).

Contract

Multiplier: 1

Strike Prices: Strike prices will be reduced by 0.24. (For example, a strike of 1.07

will be reduced to 0.83; a strike of 7.50 will be reduced to 7.26)

Option Symbol: CBIO remains CBIO

Deliverable Per

Contract: 100 Catalyst Biosciences, Inc. (CBIO) Common Shares

CUSIP: 14888D208

Disclaimer

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.